To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03724968
Title Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Elizabeth Davis
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Vanderbilt-Ingram Cancer Center Nashville Tennessee 37232 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field